MK-8294 / Merck (MSD), Janux Therapeutics - LARVOL DELTA

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (clinicaltrials.gov) - P1 | N=67 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Aug 2027 ➔ Jul 2029 | Trial primary completion date: Aug 2027 ➔ Jul 2029

Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ER • HER-2 • PGR

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (clinicaltrials.gov) - P1 | N=67 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=47 ➔ 67

Enrollment change • Monotherapy • Breast Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ER • HER-2 • PGR

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (clinicaltrials.gov) - P1 | N=47 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Oncology • Solid Tumor

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (clinicaltrials.gov) - P1 | N=47 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

Monotherapy • New P1 trial • Oncology • Solid Tumor